A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment

BACKGROUND: About 50% of patients with colorectal cancer are destined to develop hepatic metastases. Radical resection is the most effective treatment for patients with colorectal liver metastases offering five year survival rates between 36-60%. Unfortunately only 20% of patients are resectable at...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Snoeren, Nikol, Voest, Emile E, Bergman, Andre M, Dalesio, Otilia, Verheul, Henk M, Tollenaar, Rob AEM, van der Sijp, Joost RM, Schouten, Sander B, Rinkes, Inne HM Borel, van Hillegersberg, R
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2010
Teme:
Study Protocol
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2958953/
https://ncbi.nlm.nih.gov/pubmed/20937118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-10-545
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items